Table 1.
Baseline characteristics of identified studies and enrolled patients.
| Author | Year | Country | Age (Mean, Year) |
Size (Mean, mm) |
Instrument | Scale (cm/s) |
lesions | SD | DC | TP | FP | TN | FN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ma | 2015 | China | 43.7 | 22.4 | Aplio 400 | 1–2 | 123 | Pro | AC | 51 | 27 | 39 | 6 |
| Li | 2015 | China | 44.1 | 18.4 | Aplio 500 | 2.6 | 146 | Retro | AC | 38 | 13 | 86 | 9 |
| Chen | 2016 | China | 44.9 | 17.7 | Aplio 400 | 1–2 | 116 | Retro | MVDP | 42 | 6 | 57 | 11 |
| Fan | 2016 | China | 47.5 | 17.5 | Aplio 500 | 1.2 | 86 | Retro | AC | 37 | 9 | 33 | 7 |
| Zhao | 2016 | China | 44.5 | 14.9 | Aplio 500 | 1.5–2.5 | 135 | Retro | NA | NA | NA | NA | NA |
| Xiao | 2016 | China | 44.1 | 18.3 | Aplio 400 | NA | 132 | Retro | MVDP | 45 | 7 | 67 | 13 |
| Xiao | 2018 | China | 47.2 | 19 | Aplio 500 | 1–2 | 105 | Retro | MVDP | 35 | 6 | 60 | 4 |
| Park | 2019 | Korea | 45.6 | 18.7 | Aplio 500 | 3 | 98 | Pro | PV | 33 | 18 | 39 | 8 |
| PARK | 2019 | Korea | 45.6 | 18.7 | Aplio 500 | 3 | 98 | Pro | VI | 33 | 15 | 42 | 8 |
| Zhang | 2019 | China | 44.9 | 23.5 | Aplio 500 | 1.2–1.6 | 236 | Pro | VI | 92 | 39 | 76 | 19 |
| Xue | 2019 | China | NA | NA | Aplio 500 | NA | 300 | Retro | NA | NA | NA | NA | NA |
| Chu | 2020 | China | 44.4 | 19.9 | Aplio 500 | 1.2 | 142 | Retro | AC | 57 | 17 | 57 | 11 |
| Jia | 2020 | China | 48 | 22.4 | Aplio 900 | NA | 114 | Retro | MVDP | 35 | 6 | 54 | 19 |
| Wang | 2020 | China | 49.9 | 29.7 | Aplio 500 | 1.2 | 94 | Retro | AC | 32 | 9 | 48 | 5 |
| Diao | 2020 | China | 54.2 | 15.3 | Aplio 500 | 2 | 85 | Retro | PV | 32 | 6 | 40 | 7 |
| DIAO | 2020 | China | 54.2 | 15.3 | Aplio 500 | 2 | 85 | Retro | MVDP | 29 | 6 | 41 | 9 |
| Lee | 2020 | Korea | 49 | 11.3 | Aplio 800 | 2.5 | 200 | Retro | VI | 72 | 42 | 73 | 13 |
| Liang | 2020 | China | 43.9 | 17.4 | Aplio 400 | 1.2 | 177 | Pro | MVDP | 57 | 6 | 93 | 19 |
| Li | 2020 | China | 49.8 | NA | Aplio 500 | NA | 208 | Retro | NA | NA | NA | NA | NA |
| Jin | 2021 | China | NA | NA | Aplio 500 | NA | 123 | Retro | AC | 63 | 9 | 36 | 15 |
| Ran | 2021 | China | 49.4 | 20.1 | Aplio 500 | 1.2 | 150 | Pro | AC | 31 | 6 | 100 | 13 |
| Xu | 2021 | China | 53.1 | 27.7 | Aplio 800 | NA | 50 | Retro | AC | 29 | 3 | 9 | 9 |
| Zuo | 2021 | China | NA | 16 | Aplio 400 | NA | 122 | Pro | MVDP | 33 | 8 | 66 | 15 |
| Chae | 2021 | Korea | 54.1 | NA | Aplio 800 | 2.5 | 70 | Retro | VI | 31 | 3 | 31 | 5 |
| Uysal | 2021 | Turkey | 50.5 | NA | Aplio 500 | 3.5 | 121 | Retro | VI | 33 | 26 | 48 | 14 |
| Cai | 2021 | China | 46.1 | 23.5 | Aplio 500 | 1–2 | 238 | Retro | VI | NA | NA | NA | NA |
| Lee | 2021 | Korea | 46 | 10.7 | Aplio 800 | 2.5 | 88 | Retro | VI | 30 | 3 | 47 | 8 |
| Aralan | 2022 | Turkey | 49 | 21.9 | Aplio 300 | 1.5–2.5 | 90 | Retro | VI | NA | NA | NA | NA |
AC, Alder classification; DC, diagnostic criteria; FN, False negative; FP, false positive; NA, not available; PV, penetrating vessel; MVDP, microvascular distribution pattern; SD, study design; TN, true negative; TP, true positive.